Targeted Treatment for Colorectal Cancer

Tukysa (Tucatinib) is recommended for patients with metastatic HER2-positive breast cancer and RAS wild-type HER2-positive unresectable or metastatic colorectal cancer. Tucatinib is a tyrosine kinase inhibitor of HER2. In vivo, tucatinib inhibited the growth of HER2 expressing tumors. The combination of tucatinib and trastuzumab showed increased anti-tumor activity in vitro and in vivo compared to either […]